A new chemical synthesis method produces salvinorin analogs that are more potent, selective, stable, and functionally biased than the natural compound salvinorin A. These analogs target the kappa-opioid receptor and could serve as templates for next-generation pain relievers, anti-itch treatments, and dissociative hallucinogens. The synthesis uses a special organocatalyst and a cobalt-catalyzed cycloaddition to efficiently create a library of these complex molecules, overcoming previous difficulties in modifying their structure.
Deleting a single carbon atom (C20) from the complex plant metabolite salvinorin A stabilizes its molecular skeleton, simplifies its laboratory synthesis to just 10 steps, and preserves its high affinity and selectivity for the human kappa-opioid receptor. The work also introduces a general workflow for identifying structural changes that keep molecular complexity high while reducing synthetic complexity.